Afinitor everolimus regulatory update

The U.K.'s NICE issued final guidance recommending against Afinitor everolimus from Novartis for second-line treatment of advanced renal cell carcinoma (RCC). The agency said

Read the full 241 word article

How to gain access

Continue reading with a
two-week free trial.